Skip Navigation


Journal of Intellectual Property Law & Practice Advance Access originally published online on May 23, 2008
Journal of Intellectual Property Law & Practice 2008 3(7):473-478; doi:10.1093/jiplp/jpn086
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
3/7/473    most recent
jpn086v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tessensohn, J. A.
Right arrow Articles by Yamamoto, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Authors (2008). Published by Oxford University Press. All rights reserved

Crystal clear: a landmark pharma patent victory in Japan

John A. Tessensohn and Shusaku Yamamoto *

Legal context: In a landmark decision, the Intellectual Property High Court of Japan enforced a Japanese pharmaceutical patentee's crystal form patent to stop a Japanese generic drug maker, even though the basic substance patent on its blockbuster antibiotic compound had expired some 5 years earlier.

Key points: Pharmaceutical companies are extremely dependent on rigorous patent protection against relentless generic competition resulting from recently increasing patent expirations. The article provides a snapshot of similar crystal form patent litigation developments in the commercially important pharmaceutical patent jurisdictions such as Japan, the USA, and Europe.

Practical significance: Pharmaceutical patentees can now utilize crystal form or second generation patents as part of their Japanese patent strategy to enlarge the scope or length of patent protection over the product.

Key Words: Pharmaceutical patentees can use crystal form or second generation patents of basic substance patents to stop generic competition in Japan. • When enforcing such crystal form patents, they are subject to the usual patentability attacks like lack of novelty, obviousness, and lack of enablement.

* Shusaku Yamamoto, Japan. Email: jtessensohn{at}shupat.gr.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.